| 29.58 2.04 (7.41%) | 12-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 35.62 |
1-year : | 41.6 |
| Resists | First : | 30.5 |
Second : | 35.62 |
| Pivot price | 26.6 |
|||
| Supports | First : | 23.81 |
Second : | 19.69 |
| MAs | MA(5) : | 27.4 |
MA(20) : | 26.98 |
| MA(100) : | 19.12 |
MA(250) : | 0 | |
| MACD | MACD : | 1.2 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 59.8 |
D(3) : | 47.1 |
| RSI | RSI(14): 66.7 |
|||
| 52-week | High : | 30.5 | Low : | 4.17 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SEPN ] has closed above the upper band by 22.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 25.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 30.54 - 30.65 | 30.65 - 30.77 |
| Low: | 28.2 - 28.34 | 28.34 - 28.47 |
| Close: | 29.36 - 29.57 | 29.57 - 29.78 |
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
Sat, 20 Dec 2025
Is New Coverage of Septerna (SEPN) Quietly Reframing Its GPCR Platform’s Risk‑Reward Profile? - simplywall.st
Fri, 19 Dec 2025
Septerna (NASDAQ:SEPN) Reaches New 12-Month High - Should You Buy? - MarketBeat
Fri, 19 Dec 2025
Raymond James Initiates Coverage of Septerna (SEPN) with Strong Buy Recommendation - Nasdaq
Fri, 19 Dec 2025
Raymond James initiates Septerna stock with Strong Buy rating, $38 target - Investing.com UK
Wed, 17 Dec 2025
Biotech working on GPCR drugs to speak at J.P. Morgan healthcare event - Stock Titan
Mon, 15 Dec 2025
Septerna (SEPN) Receives New "Buy" Rating and $34 Price Target f - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 1.875e+007 (%) |
| Held by Institutions | 3.1 (%) |
| Shares Short | 2,030 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.79e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -266.8 % |
| Operating Margin | -46 % |
| Return on Assets (ttm) | -14.4 % |
| Return on Equity (ttm) | -22.4 % |
| Qtrly Rev. Growth | 12 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 104 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 1.48e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|